Viskase Holdings, Inc.

ENZN OTC CIK: 0000727510

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 333 EAST BUTTERFIELD ROAD, SUITE 400, LOMBARD, IL, 60148
Mailing Address 333 EAST BUTTERFIELD ROAD, SUITE 400, LOMBARD, IL, 60148
Phone (630) 874-0700
Fiscal Year End 1231
EIN 222372868

Financial Overview

FY2025 FY

$26K
Revenue
$47.17M
Total Assets
$3.01M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 27, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 27, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC

Annual Reports

10-K March 2, 2026
  • Enzon has signed a definitive agreement to merge with Viskase Companies, Inc., transforming into Viskase Holdings, Inc.
  • The company is pivoting from a pharmaceutical entity to a public acquisition vehicle, facilitating Viskase's public listing.
View Analysis

Material Events

8-K Acquisition March 26, 2026
High Impact
  • Reverse merger provides immediate public market access without a traditional IPO
  • Consolidated focus on core global meat and poultry packaging operations
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.